CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine
Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.
Authors
- Camilla Muccini (ORCID: https://orcid.org/0000-0002-0900-5639)
- Riccardo Lolatto (ORCID: https://orcid.org/0000-0002-2447-6498)
- Antonella Castagna (ORCID: https://orcid.org/0000-0002-8338-9714)
- Silvia Nozza (ORCID: https://orcid.org/0000-0002-2673-2731)
- Nicola Gianotti (ORCID: https://orcid.org/0000-0002-7182-5080)
- Sara Diotallevi (ORCID: https://orcid.org/0009-0003-2559-7042)
Institutions
- Vita-Salute San Raffaele University (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- AIDS
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1097/qad.0000000000003984
- Citations
- 4
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.17